Alvotech.
biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 63
What's happening
Earlier this month
-
Bank of America started coverage and Barclays raised its rating and target price for Alvotech.Some support1 report
-
The FDA approved a new manufacturing process for biosimilar by Alvotech, with Joseph McClellan serving as COO.Some support2 reports
-
MarketBeat provided analyst ratings for Editas Medicine and Alvotech, both of which are listed on the Nasdaq stock exchange.Some support1 report
-
Alvotech submitted a regulatory application to the European Medicines Agency (EMA).Some support1 report
One to three months ago
-
MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.Some support3 reports
-
Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.Some support3 reports
-
Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.Some support2 reports
Gone quiet
No new reports in 90+ days-
Millennium Management increased its stake in Alvotech stock, which trades on Nasdaq, with details published on MarketBeat.Some support3 reports
-
FDA closed an inspection of Alvotech's manufacturing facility located in Reykjavik, Iceland.Some support1 report
-
Alvotech listed on an electronic stock exchange and is seeking private placement investors in the European Economic Area.Some support9 reports
-
Alvotech announces that its corporate headquarters are located in Reykjavík.Some support1 report
-
Alvotech, a Nasdaq-listed company operating in North America and Europe, could benefit from Trump-era tariffs.Some support1 report
-
Alvotech is listed on Nasdaq for a public offering, targeting investors in the European Economic Area.Some support1 report
-
Alvotech announced significant operational developments, including reported results from Reykjavik, Iceland, and acquisitions of R&D facilities in Sweden and Ivers-Lee Group in Switzerland.Some support3 reports
-
Alvotech has established strategic partnerships in Europe, China, and Africa.Some support2 reports
-
Alvotech was classified in the Biomedical and Genetics industry by Zacks Medical.Some support1 report1 development inside
-
Acquisition expands capacity for Alvotech and Ivers-Lee Group while Trump-era tariffs benefit AI stocks.Some support5 reports
-
Alvotech's AVT23 is a biosimilar to Xolair.Speculative3 reports
-
A biosimilar treatment from Alvotech was approved in Europe on June 23, 2025.Speculative1 report
-
Joseph McClellan joined Alvotech as Chief Scientific Officer on June 25, 2025.Speculative1 report
-
Lenders agreed to reduce interest rates involving Alvotech and GoldenTree Asset Management.Speculative1 report
-
Alvotech and Advanz Pharma Holdco Limited entered into a supply and commercialization agreement on July 1, 2025.Speculative1 report
-
Alvotech is headquartered in Luxembourg.Speculative2 reports
-
Alvotech, Dr. Reddy’s, Sanofi, and ALK-Abelló announced expanded partnerships and product launches in India.Some support1 report
-
Teva and Alvotech formed a strategic partnership on August 1, 2025.Some support2 reports
-
Alvotech appointed Patrik Ling as VP of Investor Relations, while DNB Carnegie covered life science companies including Alvotech.Some support1 report
-
Alvotech, a UK headquartered global pharmaceutical company, received European approval for its drug Mynzepli®.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Alvotech this week
News at the entities that move Alvotech most-
FDA StructuralFDA approval coincided with Donald Trump's press conference on November 11, 2026.Moves Alvotech
-
MarketBeat Mentioned togetherHealthcare Triangle, Inc. is publicly traded on Nasdaq and receives analyst ratings from MarketBeat.Moves Alvotech
-
Africa OperationalAriana Resources plc has gold project interests in Africa and Europe.Moves Alvotech
-
Nasdaq StructuralWabtec stock joined best lists following a market growth driven by Nasdaq's performance.Moves Alvotech
-
Iceland StructuralNorway and Iceland provide technical cooperation to Arunachal Pradesh to encourage scientific innovation in the region.Moves Alvotech
-
Bank of America OperationalBank of America's CEO reported progress in the firm's wealth management division.Moves Alvotech
Connections
The 25 strongest of 63, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Alvotech's operations and product approvals are fundamentally dependent on the regulatory oversight and review processes conducted by the FDA.
-
Joseph McClellan Structural
Joseph McClellan holds senior executive roles (CSO, COO) at Alvotech.
-
Nasdaq Structural
Alvotech is formally listed and trades on the Nasdaq stock exchange.
-
Iceland Structural
Alvotech operates, manufactures, and maintains its headquarters and market listing within Iceland.
-
Africa Operational
Alvotech maintains strategic partnerships and markets biosimilars within the African region.
-
HUMIRA Operational
Alvotech is developing a biosimilar product intended to compete directly with Humira in the market.
-
Róbert Wessman Structural
Róbert Wessman serves as the Founder, Chairman, and CEO of Alvotech.
-
Bank of America Operational
Bank of America provides financial research coverage and adjusts price targets based on Alvotech's company news.
Show all 25 connections
-
GoldenTree Asset Management Transactional
Alvotech secured term loan facilities from GoldenTree Asset Management.
-
Sweden Operational
Alvotech is actively expanding its R&D and market presence in Sweden through acquisitions and stock listings.
-
European Medicines Agency Structural
Alvotech submits regulatory applications to the European Medicines Agency for product approval.
-
Stockholm Structural
Alvotech relies on its listing on Nasdaq Stockholm for investor access and global expansion.
-
European Economic Area Structural
Alvotech relies on the EEA for regulatory approval and targets investors within the bloc.
-
Millennium Management Transactional
Millennium Management increased its stake in Alvotech stock.
-
Incyte Operational
The two companies are identified as competitors within the healthcare market.
-
MarketBeat Mentioned together
MarketBeat provides financial tracking and analyst ratings for Alvotech.
-
Barclays Mentioned together
Barclays provided a rating and target price increase for Alvotech.
-
Donald Trump Structural
Alvotech's potential business benefits are tied to the policy outcomes of the Trump era.
-
Reykjavík Shared context
Alvotech operates from its headquarters located in the city of Reykjavík.
-
Europe Shared context
Alvotech conducts commercial operations and forms strategic partnerships within the European market context.
-
South America Shared context
Alvotech markets biosimilars within the South American region.
-
North America Shared context
Alvotech conducts operations within the North American market.
-
Oslo Shared context
Alvotech management is observed attending a conference in Oslo.
-
Middle East Shared context
Alvotech operates and markets biosimilars within the geographical context of the Middle East.
-
London Shared context
Alvotech management conducts business activities, such as attending conferences, within the geographical context of London.
History
Events by the month they beganOctober 2026
4 events- Bank of America started coverage and Barclays raised its rating and target price for Alvotech.
- The FDA approved a new manufacturing process for biosimilar by Alvotech, with Joseph McClellan serving as COO.
- MarketBeat provided analyst ratings for Editas Medicine and Alvotech, both of which are listed on the Nasdaq stock exchange.
- Alvotech submitted a regulatory application to the European Medicines Agency (EMA).
September 2026
1 eventAugust 2026
3 events- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
- Millennium Management increased its stake in Alvotech stock, which trades on Nasdaq, with details published on MarketBeat.
Show 2 earlier months
July 2026
1 eventJune 2026
18 events- Alvotech listed on an electronic stock exchange and is seeking private placement investors in the European Economic Area.
- Alvotech announces that its corporate headquarters are located in Reykjavík.
- Alvotech, a Nasdaq-listed company operating in North America and Europe, could benefit from Trump-era tariffs.
- Alvotech is listed on Nasdaq for a public offering, targeting investors in the European Economic Area.
- Alvotech announced significant operational developments, including reported results from Reykjavik, Iceland, and acquisitions of R&D facilities in Sweden and Ivers-Lee Group in Switzerland.
- Alvotech has established strategic partnerships in Europe, China, and Africa.
- Alvotech was classified in the Biomedical and Genetics industry by Zacks Medical.
- Acquisition expands capacity for Alvotech and Ivers-Lee Group while Trump-era tariffs benefit AI stocks.
- Alvotech's AVT23 is a biosimilar to Xolair.
- A biosimilar treatment from Alvotech was approved in Europe on June 23, 2025.
- Joseph McClellan joined Alvotech as Chief Scientific Officer on June 25, 2025.
- Lenders agreed to reduce interest rates involving Alvotech and GoldenTree Asset Management.
- Alvotech and Advanz Pharma Holdco Limited entered into a supply and commercialization agreement on July 1, 2025.
- Alvotech is headquartered in Luxembourg.
- Alvotech, Dr. Reddy’s, Sanofi, and ALK-Abelló announced expanded partnerships and product launches in India.
- Teva and Alvotech formed a strategic partnership on August 1, 2025.
- Alvotech appointed Patrik Ling as VP of Investor Relations, while DNB Carnegie covered life science companies including Alvotech.
- Alvotech, a UK headquartered global pharmaceutical company, received European approval for its drug Mynzepli®.